Bharat Biotech starts Covaxin's at-risk manufacturing


Published On: Saturday, October 24, 2020 | By:

Bharat Biotech starts Covaxin's at-risk manufacturing

Hyderabad-based vaccine maker Bharat Biotech has not only started the at-risk manufacturing of its candidate Covaxin but is also looking to ramp up capacities as India’s first indigenous Covid-19 vaccine candidate gets the nod for phase 3 trials. The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results. Besides setting up a second plant at its Genome Valley facility in Hyderabad to make Covaxin, the firm is looking for another site in the country to make the vaccine. This would be crucial as BBIL expects to forge global partnerships with international agencies like Gavi and also some countries for Covaxin by December.

We are on Telegram!

Telegram Logo

JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.

Click Here!

Follow Us On: